Achilles therapeutics announces closing of $175.5 million initial public offering

London, april 06, 2021 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing precision t cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the united states of 9,750,000 american depositary shares (“adss”) representing 9,750,000 ordinary shares, at an initial public offering price of $18.00 per ads. the gross proceeds to achilles from the offering were approximately $175.5 million. all adss sold in the offering were offered by achilles.
ACHL Ratings Summary
ACHL Quant Ranking